Mira Kaga, MD
Internal Medicine · Marlboro, NJNPI 1760707327
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,325 of the $13,494 with a category attached, or 76.5%. Merz North America, Inc. accounts for 78.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $4,608 and has fallen 84.8% since, to $700 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $53.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$11K
- AbbVie$752
- Galderma Laboratories, L.p.$716
- Novo Nordisk$417
- Takeda Pharmaceuticals U.S.A., Inc.$269
- Revance Therapeutics, Inc.$239
- plus $528 from 15 others
What the payments were for
- Travel & lodging$3,10323%
- Food & beverage$10,32577%
- Education$660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 70 | $10,574 |
| AbbVie(2 entities) | 80 | $752 |
| Galderma Laboratories, L.p. | 9 | $716 |
| Novo Nordisk | 28 | $417 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $269 |
| Revance Therapeutics, Inc. | 7 | $239 |
| Eisai Inc. | 6 | $77 |
| AstraZeneca | 4 | $55 |
| Acelrx Pharmaceuticals, Inc. | 3 | $52 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Merck | 3 | $41 |
| Amgen | 3 | $41 |
| Bausch Health US, LLC | 3 | $40 |
| Jazz Pharmaceuticals Inc. | 3 | $39 |
| Currax Pharmaceuticals LLC | 3 | $39 |
| Nalpropion Pharmaceuticals LLC | 2 | $24 |
| Forte Bio-pharma LLC | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,494 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Marlboro
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.